AZD8233 antisense oligonucleotide targeting PCSK9 does not prolong QT interval.

Dinko RekićIvan AzarovJane KnöchelVictor SokolovCatarina NilssonLinda WernevikDavid HanTina Rydén-BergstenAhmad EbrahimiCorina DotaBjörn Carlsson

Published in: British journal of clinical pharmacology (2022)

As the effect on ΔΔQTcF is below the threshold for regulatory concern (10 ms), it can be concluded that AZD8233 does not induce QTcF prolongation at the high clinical exposure scenario.

Keyphrases

drug induced
mass spectrometry
multiple sclerosis
ms ms
transcription factor
cancer therapy
drug delivery